NEW YORK, July 28, 2011 /PRNewswire via COMTEX/ --A study published by ITG this week revealed that U.S. oncologists expect Amgen's (NASDAQ: AMGN) recently approved XGEVA (denosumab) to become the top-prescribed drug over the next year for the prevention of skeletal-related events (SREs) in prostate cancer patients. Furthermore, although Novartis' (NYSE: NVS) Zometa (zoledronic acid) will likely remain the top-prescribed drug for preventing SREs in breast and lung cancer patients, physicians in the study believe XGEVA's share will more than double for these indications over the next 12 months. "Currently, Zometa maintains a dominant position in preventing skeletal-related events in pros...
↧